Latest Breaking News On - Schizophrenia psychosis action alliance - Page 1 : comparemela.com

Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign

The national initiative, Live Your PosSCZible, is focused on elevating the voices of those with schizophrenia and their care partners to drive impactful conversations about the aspirations of the.

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Prescription Drug User Fee Act action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The.

FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment

The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Prescription Drug User Fee Act action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The.

PureTech Health (PRTC) Founded Entity Karuna Therapeutics (KRTX) Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia